全文获取类型
收费全文 | 516篇 |
免费 | 34篇 |
国内免费 | 9篇 |
专业分类
儿科学 | 17篇 |
妇产科学 | 11篇 |
基础医学 | 61篇 |
口腔科学 | 10篇 |
临床医学 | 54篇 |
内科学 | 187篇 |
皮肤病学 | 10篇 |
神经病学 | 15篇 |
特种医学 | 33篇 |
外科学 | 63篇 |
综合类 | 14篇 |
预防医学 | 16篇 |
眼科学 | 4篇 |
药学 | 22篇 |
中国医学 | 1篇 |
肿瘤学 | 41篇 |
出版年
2023年 | 6篇 |
2022年 | 6篇 |
2021年 | 14篇 |
2020年 | 13篇 |
2019年 | 10篇 |
2018年 | 13篇 |
2017年 | 8篇 |
2016年 | 9篇 |
2015年 | 13篇 |
2014年 | 8篇 |
2013年 | 13篇 |
2012年 | 13篇 |
2011年 | 22篇 |
2010年 | 18篇 |
2009年 | 16篇 |
2008年 | 21篇 |
2007年 | 25篇 |
2006年 | 20篇 |
2005年 | 18篇 |
2004年 | 21篇 |
2003年 | 14篇 |
2002年 | 16篇 |
2001年 | 25篇 |
2000年 | 17篇 |
1999年 | 21篇 |
1998年 | 15篇 |
1997年 | 10篇 |
1996年 | 15篇 |
1995年 | 12篇 |
1994年 | 14篇 |
1993年 | 9篇 |
1992年 | 5篇 |
1991年 | 6篇 |
1990年 | 9篇 |
1989年 | 8篇 |
1988年 | 7篇 |
1987年 | 10篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 3篇 |
1982年 | 3篇 |
1980年 | 4篇 |
1979年 | 7篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1971年 | 2篇 |
1970年 | 2篇 |
1925年 | 1篇 |
排序方式: 共有559条查询结果,搜索用时 15 毫秒
1.
Vasundhara Sridharan Yuichi Shoda Jaimee L. Heffner Jonathan Bricker 《Substance use & misuse》2019,54(7):1086-1095
Background: Lay belief systems about the malleability of human attributes have been shown to impact behavior change in multiple domains. Addiction mindset—i.e., beliefs about the permanence (vs. malleability) of addiction — may affect cigarette smokers’ ability to quit, but this has never been examined. Objectives: The aims of the present research were to develop a measure of addiction mindset (study 1) and examine its associations with various psychological aspects of quitting smoking (study 2). Methods: In Study 1, using factor analysis of current smokers’ and nonsmokers’ (n?=?600) responses to 22 items designed to measure addiction mindset, we developed a reliable six-item Addiction Mindset Scale (AMS). In Study 2, adult smokers (n?=?200) completed the AMS, and measures of a number of psychological processes related to smoking. Results: Higher scores on the AMS, indicative of the belief that addiction is malleable (referred to as a growth mindset), were positively and significantly associated with greater motivation to quit, greater commitment to quitting, greater self-efficacy to abstain, less attribution of failure to lack of ability to change addiction, and fewer self-reported barriers to cessation (all p’s < .05). Conclusions: The results of this study show a relationship between the beliefs about the permanence of addiction and psychological processes relevant to quitting smoking. The findings underscore the potential of future research exploring how addiction mindsets relate to successful smoking cessation as well as other types of addictive behavior and how they can be applied to change people’s behavior. 相似文献
2.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
3.
4.
5.
6.
7.
J H Lee R M Brown Jr S Kuga S Shoda S Kobayashi 《Proceedings of the National Academy of Sciences of the United States of America》1994,91(16):7425-7429
Cellulose microfibrils with an electron diffraction pattern characteristic of crystalline native cellulose I have been assembled abiotically by means of a cellulase-catalyzed polymerization of beta-cellobiosyl fluoride substrate monomer in acetonitrile/acetate buffer. Substantial purification of the Trichoderma viride cellulase enzyme was found to be essential for the formation of the synthetic cellulose I allomorph. Assembly of synthetic cellulose I appears to be a result of a micellar aggregation of the partially purified enzyme and the substrate in an organic/aqueous solvent system favoring the alignment of glucan chains with the same polarity and extended chain conformation, resulting in crystallization to form the metastable cellulose I allomorph. 相似文献
8.
Shin-ichiro Shoda Akio Komenoi Tomochika Fujioka Yasunori Okumura Shiro Kobayashi 《Macromolecular chemistry and physics.》1996,197(2):633-640
Isopropoxyethyne (1a) and tert-butoxyethyne (1b) were polymerized using group 5 and 6 transition metal catalysts to give poly(isopropoxyethyne) (2a) and poly(tert-butoxyethyne) (2b) , respectively. The weight-average molecular weight (M?w) of the resulting poly(alkoxyethyne)s was up to 1.0 × 104. Among the transition metal catalysts, a tungsten alkoxide or a molybdenum alkoxide having low Lewis acidity were found to effectively promote the polymerization without causing side reactions. Poly(tert-butoxyethyne) was successfully converted to poly(β-ketone) 3 by acid hydrolysis of the tert-butyl vinyl moiety. 相似文献
9.
Shoda T Mitsumori K Onodera H Toyoda K Uneyama C Takada K Hirose M 《Toxicologic pathology》2000,28(4):540-547
Interrelationships among induction of cytochrome P-450 (CYP) 1A1/2, decrease in connexin 32 (Cx32), and liver tumor-promoting activity by beta-naphthoflavone (BNF) in the promotion stage were examined in a 2-stage liver carcinogenesis model. A total of 20 male Fischer 344 rats were initiated with a single intraperitoneal injection of 150 mg/kg of diethylnitrosamine (DEN) or were given the saline vehicle alone. Starting 2 weeks later, they were fed a diet containing 2%, 1%, or 0% BNF for 6 weeks. All animals were subjected to a two-thirds partial hepatectomy at week 3 and were sacrificed at week 8. Absolute and relative liver weights were significantly increased in the DEN+BNF groups as compared to the DEN-alone group. Diffuse hepatocellular hypertrophy with cytoplasmic eosinophilia, sometimes accompanied by development of adenoma-like hepatic foci, was observed in the BNF-treated rats. Remarkable induction of cytochrome CYP 1A1/2 and significant increase in CYP 2E1 were noted in the DEN+BNF groups, and positive immunohistochemical staining for both was observed diffusely. The areas of Cx32-positive spots per hepatocyte in the centrilobular areas of livers of the BNF-treated rats were significantly decreased, but no changes were observed in periportal areas. The numbers and areas of foci positive for glutathione S-transferase placental form were increased in the BNF-treated groups. These results suggest that BNF is a liver tumor promoter that, unlike phenobarbital, does not induce CYP 2B1/2 isozymes, and there seems to be no direct relationship between CYP 1A1/2 induction and Cx32 reduction in BNF hepatocarcinogenesis. 相似文献
10.
Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. 总被引:4,自引:0,他引:4
Toshiya Chiba Koichi Tokuuye Yasushi Matsuzaki Shinji Sugahara Yoshimichi Chuganji Kenji Kagei Junichi Shoda Masaharu Hata Masato Abei Hiroshi Igaki Naomi Tanaka Yasuyuki Akine 《Clinical cancer research》2005,11(10):3799-3805
PURPOSE: We present results of patients with hepatocellular carcinoma (HCC) treated with proton beam therapy. EXPERIMENTAL DESIGN: We reviewed 162 patients having 192 HCCs treated from November 1985 to July 1998 by proton beam therapy with or without transarterial embolization and percutaneous ethanol injection. The patients in the present series were considered unsuitable for surgery for various reasons, including hepatic dysfunction, multiple tumors, recurrence after surgical resection, and concomitant illnesses. The median total dose of proton irradiation was 72 Gy in 16 fractions over 29 days. RESULTS: The overall survival rate for all of the 162 patients was 23.5% at 5 years. The local control rate at 5 years was 86.9% for all 192 tumors among the 162 patients. The degree of impairment of hepatic functions attributable to coexisting liver cirrhosis and the number of tumors in the liver significantly affected patient survival. For 50 patients having least impaired hepatic functions and a solitary tumor, the survival rate at 5 years was 53.5%. The patients had very few acute reactions to treatments and a few late sequelae during and after the treatments. CONCLUSIONS: Proton beam therapy for patients with HCC is effective, safe, well tolerable, and repeatable. It is the useful treatment mode for either cure or palliation for patients with HCC irrespective of tumor size, tumor location in the liver, insufficient feeding of the tumor with arteries, presence of vascular invasion, impaired hepatic functions, and coexisting intercurrent diseases. 相似文献